Bridgepoint Development Capital buys outsourced drug developer Quotient Clinical


drug pharma bottleBridgepoint Development Capital has bought early-stage drug development services business Quotient Clinical from its parent company.

The company employs more than 200 people across two UK facilities, although over three-quarters of its revenues come from customers in the US and mainland Europe.

Bridgepoint partner Alan Payne said, “Quotient Clinical serves a substantial and growing market and there is significant opportunity to increase market penetration thanks to its combination of unique service offering, strong regulatory governance and a talented management team.”

Quotient said the outsourced drug development market was currently valued at $30bn and is forecast to grow at up to six per cent each year.

Last month BDC acquired a minority stake in marine and engineering consultancy LOC Group, which serves the offshore oil and gas markets.

London-headquartered LOC Group operates from 30 offices across the globe and is currently a top three global provider of marine warranty surveys for the transport and installation of offshore equipment.

Copyright © 2013 AltAssets